1α,25-Dihydroxyvitamin D3 enhances cerebral clearance of human amyloid-β peptide(1-40) from mouse brain across the blood-brain barrier
Open accessThe DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
Background: Cerebrovascular dysfunction has been considered to cause impairment of cerebral amyloid-β peptide (Aβ) clearance across the blood-brain barrier (BBB). Further, low levels of vitamin D are associated with increased risk of Alzheimer's disease, as well as vascular dysfunction. The purpose of the present study was to investigate the effect of 1α,25-dihydroxyvitamin D 3(1,25(OH)2 D3), an active form of vitamin D, on cerebral Aβ clearance from mouse brain. Methods: The elimination of [125 I]hAβ(1-40) from mouse brain was examined by using the Brain Efflux Index method to determine the remaining amount of [125 I]hAβ(1-40) radioactivity after injection into the cerebral cortex. [125 I]hAβ(1-40) internalization was analyzed using conditionally immortalized mouse brain capillary endothelial cells (TM-BBB4). Results: Twenty-four hours after intraperitoneal injection of 1,25(OH)2 D3 (1 μg/mouse), [125 I]hAβ(1-40) elimination from mouse brain was increased 1.3-fold, and the level of endogenous Aβ(1-40) in mouse brain was reduced. These effects were observed at 24 h after i.p. injection of 1,25(OH)2 D3, while no significant effect was observed at 48 or 72 h. Vitamin D receptor (VDR) mRNA was detected in mouse brain capillaries, suggesting that 1,25(OH)2 D3 has a VDR-mediated genomic action. Furthermore, forskolin, which activates mitogen-activated protein kinase kinase (MEK), enhanced [125 I]hAβ(1-40) elimination from mouse brain. Forskolin also enhanced [125 I]hAβ(1-40) internalization in TM-BBB4 cells, and this enhancement was inhibited by a MEK inhibitor, suggesting involvement of non-genomic action. Conclusions: The active form of vitamin D, 1,25(OH)2 D3, appears to enhance brain-to-blood Aβ(1-40) efflux transport at the BBB through both genomic and non-genomic actions. Compounds activating these pathways may be candidate agents for modulating Aβ(1-40) elimination at the BBB.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Shankar, G. M., Li, S., Mehta, T. H., Garcia-Munoz, A., Shepardson, N. E., Smith, I., Brett, F. M., Farrell, M. A., Rowan, M. J., Lemere, C. A., et al. (2008) · Nature Medicine · doi:10.1038/nm1782 · Cited by 3,685
Soluble Amyloid β Peptide Concentration as a Predictor of Synaptic Change in Alzheimer's Disease
Lue, L.-F., Kuo, Y.-M., Roher, A. E., Brachova, L., Shen, Y., Sue, L., Beach, T., Kurth, J. H., Rydel, R. E., & Rogers, J. (1999) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)65184-x · Cited by 1,530 · cited 1×
“Soluble Ab levels correlate with synaptic dysfunction in AD brain [41-43], and soluble Ab dimers and oligomers initially generated from Ab monomers are involved in the impairment of synaptic plasticity and memory [44,45].”
BackgroundShibata, M., Yamada, S., Kumar, S. R., Calero, M., Bading, J., Frangione, B., Holtzman, D. M., Miller, C. A., Strickland, D. K., Ghiso, J., et al. (2000) · Journal of Clinical Investigation · doi:10.1172/jci10498 · Cited by 1,413 · cited 1×
“Ab is normally produced by neurons and cleared through degradation by proteinases within the brain [2-4], as well as through elimination from the brain to the circulating blood via an efflux transport system at the blood-brain barrier (BBB) [5,6].”
BackgroundDeMattos, R. B., Bales, K. R., Cummins, D. J., Dodart, J.-C., Paul, S. M., & Holtzman, D. M. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.151261398 · Cited by 1,298
Nongenomic actions of steroid hormones
Lösel, R., & Wehling, M. (2003) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1009 · Cited by 980 · cited 1×
“As regards non-genomic actions, 1,25(OH)2D3 has been proposed to play roles in the generation of intracellular second messengers and various signal-transduction cascades [36,37].”
BackgroundIs Alzheimer's disease a neurodegenerative or a vascular disorder? Data, dogma, and dialectics
de la Torre, J. C. (2004) · The Lancet Neurology · doi:10.1016/s1474-4422(04)00683-0 · Cited by 834
Water-soluble Aβ(N-40, N-42) oligomers in normal and Alzheimer disease brains
Kuo, Y.-M., Emmerling, M. R., Vigo-Pelfrey, C., Kasunic, T. C., Kirkpatrick, J. B., Murdoch, G. H., Ball, M. J., & Roher, A. E. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.8.4077 · Cited by 618
Females exhibit more extensive amyloid, but not tau, pathology in an Alzheimer transgenic model
Hirata-Fukae, C., Li, H.-F., Hoe, H.-S., Gray, A. J., Minami, S. S., Hamada, K., Niikura, T., Hua, F., Tsukagoshi-Nagai, H., Horikoshi-Sakuraba, Y., et al. (2008) · Brain Research · doi:10.1016/j.brainres.2008.03.079 · Cited by 284
VDR gene variants associate with cognitive function and depressive symptoms in old age
Kuningas, M., Mooijaart, S. P., Jolles, J., Slagboom, P. E., Westendorp, R. G. J., & van Heemst, D. (2009) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2007.07.001 · Cited by 149 · cited 2×
“Furthermore, it was reported that single nucleotide polymorphisms in the vitamin D receptor (VDR) gene increase the risk of impairment of cognitive function and developing AD [15,16], suggesting a relation between serum vitamin D levels and risk of AD.”
BackgroundAge-related Changes in Parathyroid Hormone and 25 Hydroxycholecalciferol Levels
Chapuy, M.-C., Durr, F., & Chapuy, P. (1983) · Journal of Gerontology · doi:10.1093/geronj/38.1.19 · Cited by 132
Cited by
From blood–brain barrier to blood–brain interface: new opportunities for CNS drug delivery
Banks, W. A. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2015.21 · Cited by 1,204
Eyles, D. W., Burne, T. H. J., & McGrath, J. J. (2013) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2012.07.001 · Cited by 699
Low Serum Vitamin D Concentrations in Alzheimer's Disease: A Systematic Review and Meta-Analysis
Annweiler, C., Llewellyn, D. J., & Beauchet, O. (2013) · Journal of Alzheimer's Disease · doi:10.3233/jad-2012-121432 · Cited by 268
Consensus statement from 2nd International Conference on Controversies in Vitamin D
Giustina, A., Adler, R. A., Binkley, N., Bollerslev, J., Bouillon, R., Dawson-Hughes, B., Ebeling, P. R., Feldman, D., Formenti, A. M., Lazaretti-Castro, M., et al. (2020) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-019-09532-w · Cited by 257
Vitamin D and the brain: Genomic and non-genomic actions
Cui, X., Gooch, H., Petty, A., McGrath, J. J., & Eyles, D. (2017) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2017.05.035 · Cited by 237
Metadata
- Authors
- Ito, S., Ohtsuki, S., Nezu, Y., Koitabashi, Y., Murata, S., & Terasaki, T.
- Venue
- Fluids and Barriers of the CNS
- Published
- 2011-07-08
- Volume
- 8
- Issue
- 1
- Pages
- 20-20
- ISSN
- 2045-8118 (ISSN-L)
- OpenAlex
- W2165738353
- Cited by
- 97
- References
- 12
- FWCI
- 5.20
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: 1α,25-Dihydroxyvitamin D3 enhances cerebral clearance of human amyloid-β peptide(1-40) from mouse brain across the blood-brain barrier. https://app.cochat.ai/papers/10.1186/2045-8118-8-20
- The paper
- Ito, S., Ohtsuki, S., Nezu, Y., Koitabashi, Y., Murata, S., & Terasaki, T. (2011). 1α,25-Dihydroxyvitamin D3 enhances cerebral clearance of human amyloid-β peptide(1-40) from mouse brain across the blood-brain barrier. Fluids and Barriers of the CNS. https://doi.org/10.1186/2045-8118-8-20
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.